Feds Give $43 Million To Fast Track Development Of Ebola Vaccines
Dec 23 (Reuters) – The U.S. Department of Health and Human Services (HHS) awarded contracts worth a total of about $43 million to NewLink Genetics Corp and GlaxoSmithKline Plc for faster development of two Ebola vaccines.
Under a $30 million contract, NewLink’s unit BioProtection Systems Corp will conduct clinical trials to determine the lowest dose at which its vaccine generates an effective immune response, the HHS said. (http://1.usa.gov/1xJcwHi)
NewLink is developing the vaccine, rVSV-ZEBOV-GP, with U.S. drugmaker Merck & Co Inc, which bought worldwide commercial rights for it in November.
The contract includes an option for additional funding of $41 million.
The HHS said the contract with GSK was worth $12.9 million with an option to raise the amount by $16,000. —> Read More Here